Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 20/20 | 0.67 |
| ▸ | ESR2 | Q92731 | 19/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | TP53 | P04637 | 2/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 2/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.65 |
| ▸ | PLD2 | O14939 | 1/20 | 0.65 |
| ▸ | KDM1A | O60341 | 1/20 | 0.65 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.65 |
| ▸ | USP2 | O75604 | 1/20 | 0.65 |
| ▸ | C5 | P01031 | 1/20 | 0.65 |
| ▸ | FYN | P06241 | 1/20 | 0.65 |
| ▸ | PGR | P06401 | 1/20 | 0.65 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7571507 | 0.90 | ESR1 (0.54) | ESR1ESR2MEN1ALDH1A1LMNA | |
| SCHEMBL6836516 | 0.86 | ENPP3 (0.59) | ESR1ESR2 | |
| SCHEMBL6836831 | 0.85 | ESR1 (0.67) | ESR1ESR2MEN1ALDH1A1LMNA | |
| SCHEMBL9359344 | 0.80 | ESR1 (1.00) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Ly-117018 SCHEMBL4884822 | 0.80 | ESR1 (1.00) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Ly-117018 SCHEMBL29417500 | 0.80 | ESR1 (1.00) | ESR1ESR2MEN1ALDH1A1LMNA | |
| SCHEMBL17845185 | 0.80 | ESR1 (0.75) | ESR1ESR2MEN1ALDH1A1LMNA | |
| SCHEMBL18162075 | 0.80 | ESR1 (0.75) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Raloxifene SCHEMBL1394941 | 0.79 | ESR1 (0.96) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Ly-117018 SCHEMBL7080240 | 0.79 | ESR1 (0.98) | ESR1ESR2MEN1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 383 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264413-A1 | Compositions and Methods for Treating Female Sexual Dysfunction | PFIZER INC. | 2009-10-22 | — | — | US | claimed |
| EP-1021410-B1 | PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS | PFIZER (US) | 2006-12-27 | — | — | EP | claimed |
| EP-0946501-B1 | PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS | PFIZER (US) | 2006-05-31 | — | — | EP | claimed |
| US-6998423-B2 | Prevention of loss and restoration of bone mass by certain prostaglandin agonists | PFIZER INC. (US) | 2006-02-14 | — | — | US | claimed |
| US-20050215592-A1 | Methods for assessing, improving, or maintaining urogenital health in postmenopausal woman | PFIZER INC | 2005-09-29 | — | — | US | claimed |
| US-20050065165-A1 | Method of treating certain cancers using an estrogen agonist/antagonist | PFIZER INC | 2005-03-24 | — | — | US | claimed |
| US-20040259886-A1 | Compositions and methods for treating osteoporosis and lowering cholesterol | PFIZER INC | 2004-12-23 | — | — | US | claimed |
| US-20040176461-A1 | Prevention of loss and restoration of bone mass by certain prostaglandin agonists | PFIZER INC | 2004-09-09 | — | — | US | claimed |
| US-20040157862-A1 | Methods for treating osteoarthritis using an estrogen agonist/antagonist | PFIZER INC | 2004-08-12 | — | — | US | claimed |
| US-6649657-B2 | Administering amide to treat osteoporosis | PFIZER INC. | 2003-11-18 | — | — | US | claimed |
| EP-1021410-A1 | PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS | PFIZER INC. (US) | 2000-07-26 | — | — | EP | claimed |
| US-6069175-A | ADMINISTERING TO A MAMMAL IN NEED A THERAPEUTICALLY EFFECTIVE AMOUNT OF A MEMBER SELECTED FROM THE 4-HYDROXY TAMOXIFEN, RALOXIFENE, TOREMIFENE, CENTCHROMAN, IDOXIFENE TO TREAT ATHEROSCLEROSIS | PFIZER INC. (US) | 2000-05-30 | — | — | US | claimed |
| EP-0946501-A1 | PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS | PFIZER INC. (US) | 1999-10-06 | — | — | EP | claimed |
| EP-0911321-A2 | Compounds for the treatment of osteoporosis | PFIZER INC. (US) | 1999-04-28 | — | — | EP | claimed |
| WO-1999019300-A1 | PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS | PFIZER INC. (US) | 1999-04-22 | — | — | WO | claimed |
| WO-1998028264-A1 | PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS | PFIZER INC. (US) | 1998-07-02 | — | — | WO | claimed |
| EP-0843999-A1 | Use of estrogen agonists/antagonists for the manufacture of a medicament in the treatment of atherosclerosis independent of a lipid lowering effect | PFIZER INC. (US) | 1998-05-27 | — | — | EP | claimed |
| US-5589482-A | Benzo-thiophene estrogen agonists to treat prostatic hyperplasia | PFIZER INC. (US) | 1996-12-31 | — | — | US | claimed |
| EP-0716855-A2 | Use of estrogen agonists for treating prostatic disease, obesity and bone loss | PFIZER INC. (US) | 1996-06-19 | — | — | EP | claimed |
| WO-1995010513-A1 | BENZOTHIOPHENES AND RELATED COMPOUNDS AS ESTROGEN AGONISTS | PFIZER INC. (US) | 1995-04-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176461-A1 | Prevention of loss and restoration of bone mass by certain prostaglandin agonists | HPGDS, PTGIR, PTGER1 | ESR1 1054/4885ESR2 237/4885MEN1 3257/4885 |
| US-20050215592-A1 | Methods for assessing, improving, or maintaining urogenital health in postmenopausal woman | SHBG, GPER1, CYP19A1 | ESR1 5/4885ESR2 6/4885MEN1 2884/4885 |
| US-20040259886-A1 | Compositions and methods for treating osteoporosis and lowering cholesterol | HMGCR, SHBG, CYP46A1 | ESR1 27/4885ESR2 24/4885MEN1 1479/4885 |
| US-20040157862-A1 | Methods for treating osteoarthritis using an estrogen agonist/antagonist | GPER1, ESR2, ESR1 | ESR1 3/4885ESR2 2/4885MEN1 4738/4885 |
| US-20090264413-A1 | Compositions and Methods for Treating Female Sexual Dysfunction | PDE3A, PDE3B, PDE2A | ESR1 24/4885ESR2 40/4885MEN1 4642/4885 |
| US-20050065165-A1 | Method of treating certain cancers using an estrogen agonist/antagonist | GPER1, ESR2, ESR1 | ESR1 3/4885ESR2 2/4885MEN1 891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.